Piramal Pharma Appoints Sai Ramana Ponugoti as CEO
Shares of Piramal Pharma rose 1.70% to Rs 251.75 after the company announced the appointment of Sai Ramana Ponugoti as Chief Executive Officer (CEO) of its India Consumer Healthcare (ICH) division, effective January 6, 2025. Ponugoti succeeds Sarosh Shetty, who was serving as interim CEO.
Ponugoti brings over 20 years of leadership experience from Procter & Gamble (P&G), where he held senior roles across India and markets in Asia, the Middle East, and Africa. As the current Chief Sales Officer for P&G India, he has driven business growth through innovative strategies. During his tenure as Country Manager for P&G Vietnam, he navigated complex market conditions to achieve outstanding business and organizational results.
Piramal Pharma Limited (PPL) operates a diversified portfolio, including Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare segment, which offers over-the-counter products. The company’s global network spans 17 manufacturing facilities and over 100 countries.
In financial performance, PPL reported a 350% surge in consolidated net profit to Rs 22.59 crore for Q2 FY25, compared to Rs 5.02 crore in Q2 FY24. Revenue from operations grew 17.28% year-on-year to Rs 2,241.75 crore during the same period.
Ponugoti’s appointment marks a strategic move by Piramal Pharma to strengthen its consumer healthcare business and drive further growth in the sector.
